Myriad Genetics Earnings Call Signals Strategic Shift and Recovery
Myriad Genetics (MYGN) reported Q3 revenue of $202.7M, up 6% sequentially. Cancer Care revenue grew 1% YoY, while Prenatal Health declined 12%. Management highlighted improved margins and raised 2026 revenue guidance to $780M-$790M. The company plans to divest its Prenatal Health business to Labcorp for $210M, focusing on cancer testing.
How this was made
The 30-second read
Why it matters
The transaction provides Myriad with liquidity to fund cancer‑focused growth and may improve margins, while Labcorp expands its prenatal testing portfolio at a modest cash cost.
Market read
The deal reshapes Myriad's portfolio toward higher‑margin oncology testing and adds a modest acquisition for Labcorp, creating short‑term trading opportunities.
What to watch
Potential regulatory scrutiny of the divestiture and integration costs for Labcorp could delay expected benefits.
Background
Myriad Genetics' Q3 earnings call recapped prior quarter results and introduced a strategic divestiture of its Prenatal Health unit to Labcorp for $210 M.
Ticker impact
Myriad Genetics announced a $210 million cash sale of its Prenatal Health business to Labcorp, a new transaction not disclosed in the prior earnings release.
likely upside as investors price in stronger balance sheet and strategic focus
Deal adds $210 M cash, expected margin boost >500 bps and signals sharper focus on higher‑margin cancer portfolio.
Labcorp agreed to acquire Myriad's Prenatal Health unit for $210 million cash, a new acquisition announced in the article.
potential modest downside as the market digests the acquisition cost
Acquisition size is modest relative to Labcorp's market cap; integration risk balanced by revenue synergies.
Market effects
Strengthens the genetics testing sector focus on oncology, may pressure peers to sharpen portfolios.
U.S. biotech and diagnostics markets see modest reallocation of capital toward cancer testing.
Limited to U.S. healthcare investors; no broader macro impact.
Counterpoint
The cash outlay could be seen as overpaying for a declining prenatal business, weighing on Labcorp's near‑term earnings.
Key entities
- CompanyMyriad Genetics
Genetic testing firm focusing on cancer and mental health.
- CompanyLabcorp
Global laboratory services provider acquiring Myriad's Prenatal Health business.



